Update: Awaiting future catalysts
Can-Fite’s lead compound CF101 is continuing to advance in a Phase II/III study in psoriasis, with top-line data now expected in Q115. The company is also working on finalising a Phase III protocol for this candidate in rheumatoid arthritis (RA), although we continue to anticipate a partnership will be necessary before starting such a trial. Our new $88m rNPV (vs $90m previously) reflects minor adjustments in the timing of potential market introductions in RA and psoriasis, and continues to reflect significant upside to the current EV of $24m. The next major catalyst in H214 could be a licensing agreement (US and/or Europe) for CF101.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.